The approval of teserpaturev/G47∆ was supported by a single arm clinical phase II study in patients with residual or recurrent, supratentorial glioblastoma, after receiving radiation treatment and temozolomide, in which the stereotactic administration of teserpaturev/G47∆ intratumorally demonstrated a 1-year survival rate of 84.2% with an increasing number of tumor-infiltrating CD4+/CD8+ T cells and persistently low numbers of Foxp3+ cells in biopsies [52]. This evidence concerns the gene CD8A and neoplasm.